Auna SA · NYSE:AUNA
Auna SA — Q3 2026 Earnings Presentation
34 slides from Auna SA's earnings presentation, Nov 18, 2026
Slide 1: Q3 2026 Earnings Call Presentation
Q3 2026 Earnings Call Presentation November │ 2026 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Auna S.A. (“Auna” or the “Company”) solely for use at this presentation. This presentation contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known a
Slide 3: Today's Speakers
Today’s Speakers +30 +20 +25 Jesus Zamora Gisele Remy Lorenzo Massart Executive Chairman of the Board and Chief Financial Officer and Executive Vice President, Strategy and President Executive Vice President Equity Capital Markets • Member of the Board since 2008 and President • Chief Financial Offi
Slide 4: 3Q'26 Highlights
3Q’26 Highlights Consolidated Revenues1 +10% FXN YoY vs 3Q’25 with revenue increases across all “The third business segments. quarter Adjusted EBITDA1,2 -5% FXN YoY with 17.5% margin, impacted by specific impacts in Peru and Colombia. delivered robust Mexico’s volume recovery in its healthcare netwo
Slide 5: Consolidated 3Q26 revenue and Adjusted EBITDA with key metrics
+10% FXN revenue growth and robust cash flow reduce leverage to 3.5x. Adjusted EBITDA impacted by specific headwinds in Peru and Colombia Consolidated 3Q26 Revenue (S/) Adjusted EBITDA(1) (S/) 1,325Mn 231 Mn +19% YoY 0% YoY +10% FXN YoY -5% FXN YoY Healthcare Services Oncosalud Peru Leverage Cash Fl
Slide 6: Q3 2026 Results by Segment
Q3 2026 Results by Segment qauna
Slide 7: Mexico Healthcare Services Adj. EBITDA first quarter of YoY growth
Mexico Healthcare Services Adj. EBITDA achieved its first quarter of YoY growth. Robust surgery and oncology volumes in Monterrey successfully offset softer results from Auna Seguros caused by VAT deductibility changes. External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 24% of LTM Rev
Slide 8: Peru revenue growth driven by surgeries and B2B accounts
Peru revenue growth driven by surgeries, strategic prioritization of high-complexity procedures and greater focus on B2B accounts. Adj. EBITDA primarily impacted by accepted penalties from reconciliation of prior years’ receivables and MLR from increased healthcare plans and new B2B memberships. Ext
Slide 9: Colombia added bed capacity in Montería
Colombia added substantial bed capacity in Montería. Adj. EBITDA contracted due to an unprofitable oncology PGP contract, and medicine price caps. External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 35% of LTM Revenues 22% of LTM Adj. EBITDA 13.9% 13.1% 14.3% 8.8% 10.9% +13% (L.C) +13%
Slide 10: Q3 2026 Consolidated Results
Q3 2026 Consolidated Results 10
Slide 11: Strategic focus on high-complexity drives revenue growth across segments
Strategic focus on high-complexity and value-based care drives sustained revenue growth across all segments ▪ Mexico increased volumes YoY: +12% in surgery and +34% in oncology, with capacity utilization of 41.1%, +2.1 p.p. ▪ Peru HC network increased surgery volumes 21%, while Oncosalud’s avg. mont
Slide 12: Consolidated Adjusted EBITDA bridge 3Q'26 vs 3Q'25
Consolidated Adjusted EBITDA reflects growth and margin stabilization in Mexico, partially offset by the impacts of accepted billing penalties in Peru and the unprofitable risk-sharing contract in Colombia, which was terminated ▪ PEN/MXN depreciation of 3% and PEN/COP depreciation of 20% YoY. Adjust
Slide 13: Adjusted Net Income of S/35 million
Adjusted Net Income of S/35 million, reflecting non-cash FX impacts in 3Q25 and lower income tax expense ▪ Effective currency volatility hedging in 2026, due to Auna’s new hedging structure implemented at year-end 2025 to reset the call-spread levels and better align them with the prevailing USD/PEN
Slide 14: Free Cash Flow generation increased 95% vs 3Q25
Free Cash Flow generation increased 95% vs 3Q25 on improved collections and lower tax payments. EoP cash grows 83% vs year-end 2025. ▪ Free cash flow includes Maintenance CapEx of S/111 million, or 3.0% of revenues ▪ On track to achieve 3.0x medium term leverage target Cash flow bridge Free Cash Flo
Slide 15: Leverage ratio improved QoQ on higher end of period cash
Leverage ratio improved QoQ on 28% increase in End of Period cash Debt Structure Highlights Debt by Type (%) Debt by Currency (%) ✓ Committed to achieving 3.0x Leverage Ratio target. Consolidated Debt: S/3,746 ✓ Gross Debt decreased by PEN 7 million on a FX-neutral basis as of 3Q26. However, Term Lo
Slide 16: We reaffirm our full-year 2026 revenue guidance
“We reaffirm Peru's integrated model continues to capture growth. The healthcare services network will continue prioritizing high-complexity surgical procedures, while Oncosalud our full-year profitability should improve as onboarding from new B2B accounts normalize. 2026 revenue Mexico’s healthcare
Slide 17: Q&A
Q&A qund
Slide 18: Exhibits
Exhibits qund
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Sep-26 Δ Sep-26 Sep-26 Δ Sep-26 Sep-26 Dec-25 Sep-26 Dec-25 (USD) vs Dec-25 (USD) vs Dec-25 Assets Liabilities Current assets Current liabilities Cash and cash equivalents 179 614 335 278
Slide 20: Consolidated Statement of Income (1/2)
Consolidated Statement of Income (1/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 3Q'26 Δ 3Q'26 vs Δ YTD 26 vs 3Q'26 YTD 26 (USD) 3Q'25 YTD 25 Revenue Healthcare Services Mexico 92 316 895 20% 15% Healthcare Services Colombia 144 493 1,318 35% 26% - Healthc
Slide 21: Consolidated Statement of Income (2/2)
Consolidated Statement of Income (2/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 3Q'26 Δ 3Q'26 vs Δ YTD 26 vs 3Q'26 YTD 26 (USD) 3Q'25 YTD 25 Share of profit of equity accounted investees 1 3 8 -8% -5% Profit (loss) before tax 14 49 124 -50% -57% Income ta
Slide 22: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) YTD 26 Δ YTD 26 YTD 26 Δ YTD 26 YTD 26 YTD 25 YTD 26 YTD 25 (USD) vs YTD 25 (USD) vs YTD 25 Cash flows from operating activities Cash flows from investing activities (Loss) profit f
Slide 23: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre- operating expenses for
Slide 24: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) For the three months ended September 30, 2026 Healthcare Healthcare Healthcare Consolidated Oncosalud Holding and Services Services Services Rep
Slide 25: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Year to date September 30, 2026 Healthcare Healthcare Healthcare Consolidated Oncosalud Holding and Services Services Services Reportable Peru e
Slide 26: Consolidated Peru Adjusted EBITDA reconciliation
Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Ad
Slide 27: Adjusted Net Income reconciliation
Adjusted Net Income reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below. 3Q'26 3Q'26 3Q'25 YTD 26 YTD 25 (USD) Net Income (Loss) 7 24 53 67 175 (a)
Slide 28: Free Cash Flow
Free Cash Flow (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investing activities. Sep-25 Sep-26 Cash generated from operating activities 582 753 (-) Income t ax
Slide 29: Adjusted Basic and Diluted Earnings per Share
Adjusted Basic and Diluted Earnings per Share (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Inc
Slide 30: Net Debt reconciliation
Net Debt reconciliation (Figures in millions of Soles, unless expressed otherwise) Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents. Sep-26 Δ Sep-26 vs Sep-26 Dec-25 Sep-25 (USD) Sep-25 Dec-25 (+) Loans and borrowings 1,049 3,600 3,533 3,526 2% 2% Short t erm debt 135 46
Slide 31: Leverage Ratio reconciliation
Leverage Ratio reconciliation (Figures in millions of Soles, unless expressed otherwise) Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted
Slide 32: Key Operational Metrics – Oncosalud Peru & Healthcare Services
Key Operational Metrics – Oncosalud Peru & Healthcare Services 1) As of period end. 2) As reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Includes active plan members and inactive members. Inactive members are defined as those plan members that h
Slide 33: Trends in Key Financial Metrics
Trends in Key Financial Metrics (Figures in millions of Soles, unless expressed otherwise) 3Q'24 4Q'24 1Q'25 2Q'25 3Q'25 4Q'25 1Q'26 2Q'26 3Q'26 Revenue Oncosalud Peru 273 276 281 286 294 304 314 317 323 Healthcare Services Peru 255 245 263 269 279 273 281 296 307 Healthcare Services Colombia 363 35
Slide 34: Investor Relations
Investor Relations contact@aunainvestors.com www.aunainvestors.com 34